New AI-powered ELITE method revolutionizes breast cancer MRI diagnostics

A groundbreaking AI-based method called ELITE is set to transform the diagnosis of breast cancer through magnetic resonance imaging (MRI), according to research published on June 25, 2026. Developed by experts at Technion in Israel and the USA, ELITE combines artificial intelligence with sophisticated mathematical models to significantly enhance both the speed and accuracy of dynamic MRI scans.

Dynamic MRI already achieves over 90% accuracy in detecting breast cancer, greatly surpassing the 50-60% accuracy rates of ultrasound and mammography. However, traditional MRI methods face limitations by producing images only every one to two minutes, which hinders real-time tracking of contrast agents in tissues, crucial for identifying small tumors and distinguishing benign from malignant lesions.

ELITE addresses this challenge by integrating a deep learning system that filters image noise and reconstructs incomplete data. This innovation enables the generation of one high-quality image per second, providing continuous monitoring of contrast agent movement. Clinical studies involving 54 patients demonstrated that ELITE improved tumor visibility, image quality, and diagnostic sensitivity compared to existing MRI approaches.

Lead researcher Dr. Eddy Solomon from Technion’s biomedical engineering department explained that this breakthrough could shorten MRI scan times, increasing patient throughput and improving access to diagnostic services. While ELITE represents a major advancement in MRI-based breast cancer diagnosis, the team emphasizes that further research and clinical trials are needed before it can be widely adopted.

This advancement holds promise in better detecting approximately 2.3 million annual breast cancer cases worldwide, predominantly affecting women, by enabling faster, more precise imaging that could ultimately improve patient outcomes and expand diagnostic capacity in healthcare systems.